|
|
Volumn 33, Issue 1, 1998, Pages 39-53
|
|
Casodex® 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer: An overview of the efficacy, Tolerability and pharmacokinetics from Three Phase II Dose-ranging Studies
a
|
|
Author keywords
Advanced prostate cancer; Casodex; Dose ranging; Monotherapy; Pharmacokinetics
|
|
Indexed keywords
ACID PHOSPHATASE PROSTATE ISOENZYME;
ANALGESIC AGENT;
ANTIANDROGEN;
BICALUTAMIDE;
PROSTATE SPECIFIC ANTIGEN;
TESTOSTERONE;
ACID PHOSPHATASE;
ANILIDE;
ANTINEOPLASTIC AGENT;
ESTRADIOL;
FOLLITROPIN;
LUTEINIZING HORMONE;
ADVANCED CANCER;
AGE;
ANALYTICAL PARAMETERS;
ARTICLE;
BONE SCINTISCANNING;
CANCER PATIENT;
CARDIOVASCULAR FUNCTION;
CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE CALCULATION;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG TOLERABILITY;
ENZYME ACTIVITY;
GYNECOMASTIA;
HEMATOLOGY;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HORMONE BLOOD LEVEL;
HOT FLUSH;
HUMAN;
KIDNEY FAILURE;
KIDNEY FUNCTION;
MASTALGIA;
METASTASIS;
MULTICENTER STUDY;
ORGAN SIZE;
PAIN;
PATIENT CONTROLLED ANALGESIA;
PHASE 2 CLINICAL TRIAL;
PHYSICAL PERFORMANCE;
PRIORITY JOURNAL;
PROSTATE CANCER;
SELF REPORT;
SYMPTOMATOLOGY;
TREATMENT INDICATION;
URINARY DYSFUNCTION;
BLOOD;
CANCER INVASION;
CANCER STAGING;
COMPARATIVE STUDY;
DOSE RESPONSE;
LIVER FUNCTION TEST;
MALE;
PATHOLOGY;
PROSTATE TUMOR;
ACID PHOSPHATASE;
ANDROGEN ANTAGONISTS;
ANILIDES;
ANTINEOPLASTIC AGENTS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
ESTRADIOL;
FOLLICLE STIMULATING HORMONE;
HUMANS;
LIVER FUNCTION TESTS;
LUTEINIZING HORMONE;
MALE;
NEOPLASM INVASIVENESS;
NEOPLASM METASTASIS;
NEOPLASM STAGING;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
TESTOSTERONE;
|
|
EID: 0031614610
PISSN: 03022838
EISSN: None
Source Type: Journal
DOI: 10.1159/000019526 Document Type: Article |
|
Times cited : (63)
|
|
References (35)
|
